手里有100万，打算放3年不动，很多人第一反应就是存3年定期存款。可除了这个，还有没有别的存钱法子呢？答案当然是有的，下面就给大家唠唠。 为啥大家不愿意把钱放家里呢？其实道理很简单，现金放家里风险太大啦。万一家里进小偷，钱被偷走了，那可就血本无归；要是家里闹虫鼠蚁，钱被啃得 破破烂烂，也没法用；要是碰上洪水、地震这些天灾，钱说不定就被冲走或者埋在废墟里，找都找不回来。所以为了资金安全，很多人都会把钱交给银行打 理。 要是手里有100万闲置3年，除了3年定期存款，还有啥选择呢？ 要是你的钱不一定能闲置满3年，中间可能会提前取出来用，那存短期定期存款，到期再转存也是个办法。有些人担心，辛辛苦苦存了很久，结果提前支 取，利息损失一大笔，多心疼啊。存短期定期存款，到期转存，虽然利率可能没3年定期那么高，但能保证到期拿到满期的利息，说不定反而更划算。 还有一种办法，叫分割加组合。一种存钱方式，往往有优点也有缺点。要是只用一种方式打理大笔资金，优点缺点都会被放大。就好比活期存款，流动性 好，随时能取，可要是把100万全存成活期，利息少得可怜，想想都亏。 所以要是你有100万能闲置3年，不妨根据实际情况把资金分割一下。要是 ...

Group 1 - The core viewpoint of the article highlights a significant increase in the euro-denominated corporate bond market in June, driven by strong demand from institutional investors, proactive financing strategies by issuers, and anticipation of potential trade policy changes due to the approaching deadline for U.S. tariffs [1] - Institutional investors continue to show robust demand for credit bond assets, providing ample funding support for the primary market [1] - Corporate issuers are completing financing before the quiet period for Q2 earnings reports to avoid regulatory restrictions on issuing new securities [1] - Issuers are adopting a "prepare for the worst" strategy by locking in financing ahead of potential trade policy changes, reflecting heightened awareness of geopolitical risks [1] Group 2 - The current eurozone corporate bond issuance window exhibits a "strong supply and demand" characteristic, with investors maintaining strong demand for relatively high-yielding credit bonds amid the European Central Bank's accommodative monetary policy [1] - Issuers are taking advantage of favorable market conditions for proactive liability management, meeting operational funding needs while preparing liquidity reserves for potential changes in the trade environment [1] - Some multinational companies have noticeably accelerated the pace of euro bond issuance, indicating market participants' heightened vigilance regarding geopolitical risks [1]

Core Insights - Bitcoin Treasury Corporation has completed the initial phase of its Bitcoin accumulation plan, acquiring 478.57 Bitcoin for CAD$70 million, bringing its total holdings to 771.37 Bitcoin [1] - The Corporation aims to build long-term shareholder value by deploying its Bitcoin holdings through institutional lending and liquidity services, viewing Bitcoin as a foundational pillar of its business model [2] Company Strategy - The core strategy of Bitcoin Treasury Corporation is to accumulate and actively deploy Bitcoin to enhance shareholder value, recognizing Bitcoin's finite supply and long-term potential [3] - The Corporation plans to maintain a robust treasury position while expanding its service offerings, particularly in Bitcoin-denominated loans [3] Financial Metrics - The acquisition of Bitcoin results in a starting Bitcoin per Share (BPS) of approximately 0.0000634, calculated on a fully diluted basis [1]

Key Takeaways LMT won a $250M contract to supply F-35 logistics systems, including ODIN and MPE hardware, by August 2027. The deal supports the U.S. Air Force, Navy, Marine Corps, FMS customer and F-35 program partners. Work will be performed in Orlando, FL, and Fort Worth, TX, under the Naval Air Systems Command contract.Lockheed Martin Corporation (LMT) recently clinched a modification contract involving the F-35 Lightning II fighter aircraft program. The award has been provided by the Naval Air Systems ...

Core Viewpoint - Autonomix Medical, Inc. has received a significant patent that enhances its position in the nerve-focused therapeutics market, supporting its mission to provide minimally invasive treatments for various nerve-related conditions [1][2]. Group 1: Patent and Technology - The newly issued U.S. Patent No. 12,279,889 B2 ('889 patent) relates to advanced systems for evaluating and modifying neurological functions, including tools for accessing small vessels and treating cancerous tumors [1][3]. - The technology includes integrated sensors in microneedles for deep tissue access, multiband optical sensors for tissue viability, and control systems that adjust treatment based on feedback signals [3][4]. - Autonomix's platform utilizes a catheter-based microchip sensing array that can detect neural signals with greater sensitivity than existing technologies, enabling a precision-guided approach to treat chronic pain and other conditions [4][6]. Group 2: Market Opportunity and Clinical Trials - The patent strengthens Autonomix's intellectual property portfolio, which now includes over 80 issued patents, positioning the company in a multi-billion-dollar market opportunity [1][2]. - The company plans to submit an Investigational Device Exemption (IDE) and begin U.S. clinical trials in 2025 for its Sensing and RF Ablation System, targeting pancreatic cancer pain [5][7]. - The technology aims to address a wide range of conditions influenced by sympathetic nerve activity, including hypertension and chronic pain syndromes, with the potential for numerous applications across various medical fields [1][7].

Core Insights - NIO has officially launched the Cedar 1.1.0 system upgrade for its flagship sedan ET9, introducing over 30 new and optimized features across four core areas: smart safety, intelligent driving, smart cockpit, and comfortable driving experience [1][2]. Smart Safety - The ET9 upgrade features the industry's first mass-produced emergency autonomous roadside parking function, which allows the vehicle to slow down and steer to the right side of the road if the driver is unresponsive [1]. - Additional active safety features include Automatic Emergency Steering (AES), Emergency Active Parking (EAS), and Emergency Lane Keeping (ELK), creating a comprehensive safety protection system [1]. - The smart high-definition projection headlights offer pixel-level precise zone lighting, enhancing nighttime driving safety by highlighting potential risks ahead [1]. Intelligent Driving - The NIO World Model (NWM) is now in mass production on the ET9, enabling point-to-point navigation assistance (NOP+) for both highways and urban areas, including support for ETC toll station assistance [1]. - The parking scenario has been improved with features like parking space collection, allowing the vehicle to autonomously park upon reaching a designated area [1][2]. Comfort and Experience - The ET9 introduces 4D Global Comfort Navigation technology, which integrates sensing hardware and cloud data to create a 4D road condition map, effectively reducing road impact [2]. - The smart cockpit features the "Leap Over Skyline" immersive experience, integrating multiple screens, an advanced sound system, and smart climate control, with new multi-screen playback capabilities [2]. - The NOMI smart assistant has been enhanced with spatial exploration and interaction features, allowing users to inquire about geographic information and receive visual feedback through gestures [2]. Upcoming Features - The first version of Cedar 1.1.0 will soon be pushed to new models including the ES6, EC6, ET5, and ET5T [3].

Core Insights - The shift from traditional SEO to AI-powered search necessitates that brands optimize their product data to enhance visibility and relevance in search results [1][2][3] - Generative AI is expected to significantly influence ecommerce, with predictions indicating it could impact up to 19% of global Cyber Five sales, equating to approximately $61 billion in spending [3] Company Developments - BigCommerce and Feedonomics have integrated the AI-powered search engine Perplexity to provide customers with enhanced product visibility in AI search results [1][2] - Feedonomics supplies Perplexity with pre-optimized, structured product data, improving the accuracy and contextual relevance of search results for merchants [2][3] Industry Trends - The emergence of agentic shopping, where AI agents assist consumers in their purchasing decisions, highlights the importance of high-quality product catalogs and optimized data transfers [4][5] - The demand for agentic experiences in shopping is growing, with consumers increasingly relying on AI for accurate product information and recommendations [5] Strategic Implications - Brands must ensure their product data is structured and accessible to AI search channels to drive relevance, customer loyalty, and growth in a competitive digital landscape [3][4] - The collaboration between BigCommerce, Feedonomics, and Perplexity aims to set a new standard for ecommerce search by delivering AI-ready data that enhances search experiences and conversion rates [5]

Core Viewpoint - Enzo Biochem, Inc. has entered into a Merger Agreement with Battery Ventures, which will acquire Enzo for $0.70 per share in cash, totaling approximately $37 million, following a strategic review to maximize shareholder value [1][2][3]. Summary by Sections Merger Agreement - The Merger Agreement was signed on June 23, 2025, and Battery Ventures will acquire Enzo for $0.70 per share, amounting to about $37 million [1]. - The purchase price represents a 75% premium over Enzo's closing price on April 22, 2025, and a 32% premium over the closing price on June 23, 2025 [2]. Strategic Committee Insights - The Board of Directors, through the Strategic Committee, conducted a thorough evaluation of options to maximize shareholder value and unanimously agreed that the all-cash offer from Battery provides immediate and compelling value [3]. - The transaction is subject to customary closing conditions, including shareholder approval, and is expected to close in the third quarter of the calendar year [3]. Post-Merger Status - Upon closing, Enzo will become a privately held company, and its shares will no longer be listed on public exchanges [4]. - BroadOak Capital Partners served as the financial advisor, and BakerHostetler LLP acted as legal counsel for the transaction [4]. Company Overview - Enzo Biochem has been a life sciences company for over 45 years, primarily operating through its Life Sciences division, focusing on labeling and detection technologies [5]. - The company offers a comprehensive portfolio of products, including antibodies, genomic probes, assays, biochemicals, and proteins, which are essential in translational research and drug development [5].

Core Insights - Tempus AI reported $193.8 million in Genomics revenues for Q1 2025, marking an increase of nearly 89% year over year, driven by a 20% growth in oncology test volumes and higher average revenue per test due to increased Medicare reimbursement rates [1][8] - The company is set to launch a new liquid biopsy assay, xM for treatment response monitoring, which will track changes in tumor fraction during immune-checkpoint inhibitor therapies, potentially influencing treatment decisions [2] - Tempus is also preparing to launch its first whole-genome sequencing test, Xh, aimed at detecting clinically relevant variants in hematological oncology by next year [3] - A companion diagnostic test is being developed in collaboration with Verastem Oncology, leveraging Tempus' FDA-approved xT CDx assay in clinical trials for ovarian cancer treatment [4] Industry Updates - Guardant Health reported a 20% year-over-year growth in oncology revenues, with a 25% increase in test volumes, and launched a hereditary cancer test [5] - Exact Sciences is experiencing strong international adoption of its Oncotype DX genomic test and has launched Cologuard Plus, which is expected to reduce false positives significantly [6] Financial Performance - Tempus AI shares have increased by 105.3% year to date, outperforming the industry average growth of 28% [7] - The company is trading at a forward Price-to-Sales ratio of 8.60X, compared to the industry average of 6.02X [9] - The Zacks Consensus Estimate for Tempus AI's 2025 earnings has been trending upward over the past 90 days, indicating positive market sentiment [11]

Core Viewpoint - Enzo Biochem, Inc. reported a decline in revenue and gross margin for the fiscal third quarter ended April 30, 2025, while also announcing strategic reviews and a class-wide settlement related to a cyber incident [1][6][3]. Financial Highlights - The company's third-quarter revenue was $6.4 million, a decrease of $1.6 million or 20% compared to the same period last year [6]. - Gross margin percentage for the third quarter was 39%, down from 47% in the previous year, primarily due to reduced revenues not covering fixed manufacturing costs [6]. - The net loss per basic and fully diluted share was ($0.05) for the three months ended April 30, 2025, compared to ($0.06) for the same period in 2024 [6]. Recent Events - A class-wide settlement agreement related to an April 2023 cyber incident was approved, with $0.8 million paid in March 2025 and a remaining balance of $6.7 million due by July 10, 2025 [3]. - The Board of Directors initiated a review of strategic alternatives, forming a special committee to explore options including potential transactions or returning excess capital to shareholders [4]. - The company voluntarily delisted its common stock from NYSE, with trading on OTCQX commencing on April 21, 2025 [5]. Company Overview - Enzo Biochem has been operating for over 45 years, focusing on life sciences through its Enzo Life Sciences division, which offers a wide range of products for research and drug development [5]. - The company launched approximately 100 new products in the third quarter of fiscal year 2025, aiming to drive new revenues [6]. Balance Sheet Data - As of April 30, 2025, the company had cash and cash equivalents of $36.7 million and working capital of $31.3 million [12]. - Stockholders' equity decreased to $43.4 million from $56.1 million as of July 31, 2024 [12].